AG-URSODIOL TABLET

Country: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

URSODIOL

Disponibbli minn:

ANGITA PHARMA INC.

Kodiċi ATC:

A05AA02

INN (Isem Internazzjonali):

URSODEOXYCHOLIC ACID

Dożaġġ:

500MG

Għamla farmaċewtika:

TABLET

Kompożizzjoni:

URSODIOL 500MG

Rotta amministrattiva:

ORAL

Unitajiet fil-pakkett:

15G/50G

Tip ta 'preskrizzjoni:

Prescription

Żona terapewtika:

CHOLELITHOLYTIC AGENTS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0122789002; AHFS:

L-istatus ta 'awtorizzazzjoni:

APPROVED

Data ta 'l-awtorizzazzjoni:

2020-09-23

Karatteristiċi tal-prodott

AG-Ursodiol (Ursodiol Tablets)
_ _
Page 1 of 32
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
AG-URSODIOL
Ursodiol Tablets
Tablets, 250 mg & 500 mg, Oral
USP
Bile Acid Preparation
Angita Pharma Inc.
1310 rue Nobel
Boucherville, Quebec
J4B 5H3, Canada
Date of Initial Authorization:
September 23, 2020
Date of Revision:
September 26, 2023
Submission Control Number: 278847
AG-Ursodiol (Ursodiol Tablets)
_ _
Page 2 of 32
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, Gastrointestinal
09/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED .
RECENT MAJOR LABEL CHANGES
..........................................................................................
2
TABLE OF CONTENTS
............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................................... 4
1
INDICATIONS
............................................................................................................
4
1.1
Pediatrics
.............................................................................................................................
4
1.2
Geriatrics
.............................................................................................................................
4
2
CONTRAINDICATIONS
...............................................................................................
4
4
DOSAGE AND ADMINISTRATION
...............................................................................
4
4.1
Dosing Considerations
........................................................................................................
4
4.2
Recommended Dose and Dosage Adjustment
................................................................... 5
4.3
Administration
....................................................................................................................
5
4.4
Missed Dose
.....................